23 related articles for article (PubMed ID: 38662151)
1. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
[TBL] [Abstract][Full Text] [Related]
2. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
3. The
Ampudia-Mesias E; Cameron CS; Yoo E; Kelly M; Anderson SM; Manning R; Abrahante Lloréns JE; Moertel CL; Yim H; Odde DJ; Saydam N; Saydam O
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674001
[TBL] [Abstract][Full Text] [Related]
4. A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer.
Lagerweij T; Hiddingh L; Biesmans D; Crommentuijn MH; Cloos J; Li XN; Kogiso M; Tannous BA; Vandertop WP; Noske DP; Kaspers GJ; Würdinger T; Hulleman E
Oncotarget; 2016 Jun; 7(24):35776-35788. PubMed ID: 26967057
[TBL] [Abstract][Full Text] [Related]
5. Melanoma antigens in pediatric medulloblastoma contribute to tumor heterogeneity and species-specificity of group 3 tumors.
Collins RRJ; Gee RRF; Sanchez MCH; Tozandehjani S; Bayat T; Breznik B; Lee AK; Peters ST; Connelly JP; Pruett-Miller SM; Roussel MF; Rakheja D; Tillman HS; Potts PR; Fon Tacer K
bioRxiv; 2024 May; ():. PubMed ID: 38798351
[TBL] [Abstract][Full Text] [Related]
6. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.
Menyhárt O; Giangaspero F; Győrffy B
J Hematol Oncol; 2019 Mar; 12(1):29. PubMed ID: 30876441
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup.
Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V
Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068
[TBL] [Abstract][Full Text] [Related]
8. Primary microcephaly gene CENPE is a novel biomarker and potential therapeutic target for non-WNT/non-SHH medulloblastoma.
Fang H; Zhang Y; Lin C; Sun Z; Wen W; Sheng H; Lin J
Front Immunol; 2023; 14():1227143. PubMed ID: 37593739
[TBL] [Abstract][Full Text] [Related]
9. Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy.
Chaturvedi NK; Kling MJ; Coulter DW; McGuire TR; Ray S; Kesherwani V; Joshi SS; Sharp JG
Oncotarget; 2018 Mar; 9(24):16619-16633. PubMed ID: 29682173
[TBL] [Abstract][Full Text] [Related]
10. Integration of immunohistochemistry, RNA sequencing, and multiplex ligation-dependent probe amplification for molecular classification of pediatric medulloblastoma.
Huang HY; Yu CH; Yang YL; Chang YH; Jou ST; Lin KH; Lu MY; Chang HH; Chou SW; Ni YL; Lin DT; Chen HY; Peng SS; Kuo MF; Yang SH
Pediatr Blood Cancer; 2022 Apr; 69(4):e29569. PubMed ID: 35119194
[TBL] [Abstract][Full Text] [Related]
11. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
[TBL] [Abstract][Full Text] [Related]
12. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
